Taro Inks $36M Investor Deal Over Generics Price-Fixing <https://www.law360.com/competition/articles/1825670?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-04-16&read_main=1&nlsidx=0&nlaidx=1> By Lauren Berg Taro Pharmaceutical Industries shareholders asked a New York federal judge Monday to greenlight a $36 million settlement resolving proposed class claims that the company misled investors about alleged generic drug price-fixing that led to a drop in stock price upon news of a U.S. Department of Justice antitrust investigation. Motion attached | Read full article » <https://www.law360.com/competition/articles/1825670?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-04-16&read_more=1&nlsidx=0&nlaidx=1> | Save to favorites » <https://www.law360.com/competition/articles/1825670?nl_pk=6416fd97-1dc4-4e02-b7d8-a89ca44ecaf4&utm_source=newsletter&utm_medium=email&utm_campaign=competition&utm_content=2024-04-16&read_later=1&nlsidx=0&nlaidx=1>